In clinical practice, the prognosis of patients with BRAF mutations are the poorest (especially V600E mutation), even worse than mutant KRAS G12D/13D. Recurrence and PM are commonly seen after radical surgery in CRC with BRAF mutant and chemotherapy are resistant in these patients. This evidence concerns the gene KRAS and colorectal carcinoma.